Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helmut R Maecke

Showing results (71-80 of 86) with videos related to

Pageof 9
Sort By:
Journal of Medicinal Chemistry|April 5, 2011
Highly improved metabolic stability and pharmacokinetics of indium-111-DOTA-gastrin conjugates for targeting of the gastrin receptorPetra Kolenc-Peitl, Rosalba Mansi, MariaLuisa Tamma, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 3, 2007
Indication for different mechanisms of kidney uptake of radiolabeled peptidesMartin Gotthardt, Julliëtte van Eerd-Vismale, Wim J G Oyen, et al.
American Journal of Nuclear Medicine and Molecular Imaging|January 28, 2015
Survival after somatostatin based radiopeptide therapy with (90)Y-DOTATOC vs. (90)Y-DOTATOC plus (177)Lu-DOTATOC in metastasized gastrinomaRebecca A Dumont, Daniela Seiler, Nicolas Marincek, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 15, 2010
Imaging expression of the human somatostatin receptor subtype-2 reporter gene with 68Ga-DOTATOCHanwen Zhang, Maxim A Moroz, Inna Serganova, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 18, 2011
PET of somatostatin receptor-positive tumors using 64Cu- and 68Ga-somatostatin antagonists: the chelate makes the differenceMelpomeni Fani, Luigi Del Pozzo, Keelara Abiraj, et al.
Journal of Translational Medicine|January 17, 2013
Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation studyNicolas Marincek, Ann-Catherine Jörg, Philippe Brunner, et al.
EJNMMI Research|August 3, 2018
The tetraamine chelator outperforms HYNIC in a new technetium-99m-labelled somatostatin receptor 2 antagonistKeelara Abiraj, Samer Ursillo, Maria Luisa Tamma, et al.
Theranostics|March 1, 2014
Positron emission tomography (PET) imaging of prostate cancer with a gastrin releasing peptide receptor antagonist--from mice to menGesche Wieser, Rosalba Mansi, Anca L Grosu, et al.
Molecular Pharmaceutics|July 2, 2015
Copper-64 Labeled Macrobicyclic Sarcophagine Coupled to a GRP Receptor Antagonist Shows Great Promise for PET Imaging of Prostate CancerEleni Gourni, Luigi Del Pozzo, Emilie Kheirallah, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 14, 2017
Safety, Biodistribution, and Radiation Dosimetry of <sup>68</sup>Ga-OPS202 in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase I Imaging StudyGuillaume P Nicolas, Seval Beykan, Hakim Bouterfa, et al.
Pageof 9

Showing results (71-80 of 86) with videos related to

Sort By:
Pageof 9
Journal of Medicinal Chemistry|April 5, 2011
Highly improved metabolic stability and pharmacokinetics of indium-111-DOTA-gastrin conjugates for targeting of the gastrin receptorPetra Kolenc-Peitl, Rosalba Mansi, MariaLuisa Tamma, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 3, 2007
Indication for different mechanisms of kidney uptake of radiolabeled peptidesMartin Gotthardt, Julliëtte van Eerd-Vismale, Wim J G Oyen, et al.
American Journal of Nuclear Medicine and Molecular Imaging|January 28, 2015
Survival after somatostatin based radiopeptide therapy with (90)Y-DOTATOC vs. (90)Y-DOTATOC plus (177)Lu-DOTATOC in metastasized gastrinomaRebecca A Dumont, Daniela Seiler, Nicolas Marincek, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 15, 2010
Imaging expression of the human somatostatin receptor subtype-2 reporter gene with 68Ga-DOTATOCHanwen Zhang, Maxim A Moroz, Inna Serganova, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 18, 2011
PET of somatostatin receptor-positive tumors using 64Cu- and 68Ga-somatostatin antagonists: the chelate makes the differenceMelpomeni Fani, Luigi Del Pozzo, Keelara Abiraj, et al.
Journal of Translational Medicine|January 17, 2013
Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation studyNicolas Marincek, Ann-Catherine Jörg, Philippe Brunner, et al.
EJNMMI Research|August 3, 2018
The tetraamine chelator outperforms HYNIC in a new technetium-99m-labelled somatostatin receptor 2 antagonistKeelara Abiraj, Samer Ursillo, Maria Luisa Tamma, et al.
Theranostics|March 1, 2014
Positron emission tomography (PET) imaging of prostate cancer with a gastrin releasing peptide receptor antagonist--from mice to menGesche Wieser, Rosalba Mansi, Anca L Grosu, et al.
Molecular Pharmaceutics|July 2, 2015
Copper-64 Labeled Macrobicyclic Sarcophagine Coupled to a GRP Receptor Antagonist Shows Great Promise for PET Imaging of Prostate CancerEleni Gourni, Luigi Del Pozzo, Emilie Kheirallah, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 14, 2017
Safety, Biodistribution, and Radiation Dosimetry of <sup>68</sup>Ga-OPS202 in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase I Imaging StudyGuillaume P Nicolas, Seval Beykan, Hakim Bouterfa, et al.
Pageof 9